Trial Profile
Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms REGOLAND
- 03 Jul 2021 Results (n=100) assessing prospective validation of Ang-2 and Tie-2 plasma levels, presented at the 23rd World Congress on Gastrointestinal Cancer.
- 10 Dec 2020 Status changed from active, no longer recruiting to completed.
- 04 Oct 2020 This trial is completed in UK (Global End Date: 05 Dec 2018), according to European Clinical Trials Database record.